Search research articles
Contact Us
Filters
Showing results (61-70 of 143) with videos related to
Page
of 15
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 30, 2016
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
Philippe Armand, Margaret A Shipp, Vincent Ribrag, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 17, 2013
A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission
Neha Mehta, Jocelyn C Maragulia, Allison Moskowitz, et al.
Blood Advances
|
September 18, 2023
Prognostic model using 18F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma
Julia Driessen, Gerben J C Zwezerijnen, Heiko Schöder, et al.
Leukemia & Lymphoma
|
June 11, 2014
Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma
Tim Illidge, Reda Bouabdallah, Robert Chen, et al.
British Journal of Haematology
|
March 18, 2011
Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres
Stephen D Smith, Craig H Moskowitz, Robert Dean, et al.
Leukemia & Lymphoma
|
August 20, 2021
Prognostic value of presalvage metabolic tumor volume in patients with relapsed/refractory diffuse large B-cell lymphoma
Juan Pablo Alderuccio, Russ A Kuker, Priscila Barreto-Coelho, et al.
Blood
|
April 5, 2003
Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma
Paul A Hamlin, Andrew D Zelenetz, Tarun Kewalramani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 28, 2010
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era
Christian Gisselbrecht, Bertram Glass, Nicolas Mounier, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
November 10, 2009
Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantation
Trudy N Small, Andrew D Zelenetz, Ariela Noy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 13, 2013
Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial
Julie M Vose, Shelly Carter, Linda J Burns, et al.
Page
of 15
Search research articles
Search
Showing results (61-70 of 143) with videos related to
Sort By:
Page
of 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 30, 2016
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
Philippe Armand, Margaret A Shipp, Vincent Ribrag, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 17, 2013
A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission
Neha Mehta, Jocelyn C Maragulia, Allison Moskowitz, et al.
Blood Advances
|
September 18, 2023
Prognostic model using 18F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma
Julia Driessen, Gerben J C Zwezerijnen, Heiko Schöder, et al.
Leukemia & Lymphoma
|
June 11, 2014
Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma
Tim Illidge, Reda Bouabdallah, Robert Chen, et al.
British Journal of Haematology
|
March 18, 2011
Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres
Stephen D Smith, Craig H Moskowitz, Robert Dean, et al.
Leukemia & Lymphoma
|
August 20, 2021
Prognostic value of presalvage metabolic tumor volume in patients with relapsed/refractory diffuse large B-cell lymphoma
Juan Pablo Alderuccio, Russ A Kuker, Priscila Barreto-Coelho, et al.
Blood
|
April 5, 2003
Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma
Paul A Hamlin, Andrew D Zelenetz, Tarun Kewalramani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 28, 2010
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era
Christian Gisselbrecht, Bertram Glass, Nicolas Mounier, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
November 10, 2009
Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantation
Trudy N Small, Andrew D Zelenetz, Ariela Noy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 13, 2013
Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial
Julie M Vose, Shelly Carter, Linda J Burns, et al.
Page
of 15